Skip to main content
. Author manuscript; available in PMC: 2024 Mar 18.
Published in final edited form as: Biometrics. 2023 Feb 7;79(2):1057–1072. doi: 10.1111/biom.13716

Table 2:

Variance estimates based on 10,000 simulation runs; the probability of treatment in the collection of trials was estimated by averaging the trial-specific treatment probabilities.

a n s=13ns Balanced TxAM varies ψ^aug(a) ψ^g(a) ψ^w(a)
1 10000 2000 Yes No 0.0105 0.0038 0.2893
1 10000 2000 Yes Yes 0.0084 0.0035 0.1945
1 10000 2000 No No 0.0101 0.0038 0.2167
1 10000 2000 No Yes 0.0088 0.0038 0.1925
1 100000 2000 Yes No 0.0144 0.0039 0.3316
1 100000 2000 Yes Yes 0.0120 0.0035 0.3610
1 100000 2000 No No 0.0143 0.0039 0.4028
1 100000 2000 No Yes 0.0128 0.0037 0.2925
0 10000 2000 Yes No 0.0103 0.0039 0.1165
0 10000 2000 Yes Yes 0.0131 0.0042 0.1509
0 10000 2000 No No 0.0101 0.0039 0.1136
0 10000 2000 No Yes 0.0118 0.0040 0.1551
0 100000 2000 Yes No 0.0151 0.0039 0.1873
0 100000 2000 Yes Yes 0.0198 0.0043 0.2699
0 100000 2000 No No 0.0146 0.0038 0.1663
0 100000 2000 No Yes 0.0218 0.0040 0.3243

In the column titled Balanced, Yes denotes scenarios in which the trials had on average equal sample sizes; No denotes scenarios with unequal trial sample sizes. In the column titled TxAM varies, Yes denotes scenarios in which the treatment assignment mechanism varied across trials; No denotes scenarios in which the mechanism did not vary.